Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Identification of a Novel AML Patient Subset Sensitive to Venetoclax Using Matched Proteomics and Diverse Ex Vivo Models

Pilgrim Jackson, Derek Stirewalt, James Sorrentino, Salvador Martinez de Bartolome Izquierdo, Mahan Abbasian, Robert Bates, Jasmine Naru

Blood (2023) 142 (Supplement 1): 4338.

https://doi.org/10.1182/blood-2023-189841

Published: 2023

Journal Articles

Characteristics and Prognostic Effects of DNMT3A Co-Mutations

Blood (2022) 140 (Supplement 1): 745–747.

https://doi.org/10.1182/blood-2022-162526

Published: 2022

Journal Articles

A Robust Long Non-Coding RNA Expression Classifier for Risk Stratification in Pediatric AML

Jason E Farrar, Jenny L. Smith, Megan Othus, Benjamin J. Huang, Yi-Cheng Wang, Rhonda E. Ries, Tiffany A. Hylkema, Era L Pogosova-Agadjanyan, Sneha Challa, Amanda R. Leonti, Timothy I. Shaw, Timothy Junius Triche, Jr., Alan S. Gamis, Richard Aplenc, Anders E. Kolb, Xiaotu Ma, Derek Stirewalt, Todd A. Alonzo, Soheil Meshinchi

Blood (2022) 140 (Supplement 1): 9173–9174.

https://doi.org/10.1182/blood-2022-168296

Published: 2022

Journal Articles

Requirement for N 6 -Methyladenosine mRNA Methylation during Human Erythropoiesis

Daniel Kuppers, Yong Peng, Sonali Arora, Cindy Wladyka, Anne Wilhite, Derek Stirewalt, Beverly Torok-Storb, Andrew Hsieh, Chuan He, Patrick Paddison

Blood (2022) 140 (Supplement 1): 8163.

https://doi.org/10.1182/blood-2022-168316

Published: 2022

Journal Articles

Therapeutic Targeting of Spliceosome Mutant Myeloid Neoplasms Via PARP1 Inhibition

Sayantani Sinha, Zhiyan Silvia Liu, Maxwell Bannister, Erica Arriaga-Gomez, Axia Song, Dawei Zong, Martina Sarchi, Elizabeth Bonner, Victor Corral, Cassandra Leibson, Wannasiri Chiraphapphaiboon, Derek Stirewalt, Joachim Deeg, Sumit Rai, Matthew J Walter, Timothy A. Graubert, Sergei Doulatov, Dang Hai Nguyen, Stanley Chun-Wei Lee

Blood (2022) 140 (Supplement 1): 217–219.

https://doi.org/10.1182/blood-2022-170574

Published: 2022

Journal Articles

MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia By Enhancing Common β Chain Cytokine Receptor Endocytosis

Blood (2021) 138 (Supplement 1): 59.

https://doi.org/10.1182/blood-2021-151559

Published: 2021

Journal Articles

Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report

Blood (2021) 138 (Supplement 1): 522.

https://doi.org/10.1182/blood-2021-151246

Published: 2021

Journal Articles

Global Proteomic Profiling Identifies Novel Prognostic Factors in Undifferentiated Leukemia Blasts from Patients with NPM1 Mutations: A Previously Unreported Approach to Biomarker Discovery from the Fred Hutch and SWOG

Blood (2021) 138 (Supplement 1): 799.

https://doi.org/10.1182/blood-2021-151678

Published: 2021

Journal Articles

A Shared SF3B1 Neoantigen Is Presented on Primary Malignant Cells and Induced Pluripotent Stem Cell-Derived Hematopoietic Lines

Melinda Ann Biernacki, Kimberly A Foster, Courtnee Clough, Stephanie Busch, B.S., Carrie Cummings, Vivian G. Oehler, MD, Derek Stirewalt, MD, Sergei Doulatov, PhD, Marie Bleakley, MBBS MMSc PhD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-139907

Published: 2020

Journal Articles

Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-134211

Published: 2020

Journal Articles

Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

Blood (2019) 134 (Supplement_1): 2691.

https://doi.org/10.1182/blood-2019-124529

Published: 2019

Journal Articles

2 nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials

Megan Othus, PhD, Elihu H. Estey, MD, Guillermo Garcia-Manero, MD, Brent Wood, MD PhD, Derek Stirewalt, MD, John Godwin, MD, James K. Weick, MD, Jeanne E. Anderson, MD, Frederick R. Appelbaum, MD, Harry P. Erba, MD PhD, Roland B. Walter, MD PhD MS

Blood (2018) 132 (Supplement 1): 3978.

https://doi.org/10.1182/blood-2018-99-117525

Published: 2018

Journal Articles

Associations between Complete Remissions (CRs) with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia and 2-3 Year Survival ("Potential Cure") over the Past Four Decades: Analysis of SWOG Trial Data

Megan Othus, PhD, Guillermo Garcia-Manero, MD, John Godwin, MD, James K. Weick, MD, Jeanne E. Anderson, MD, Derek Stirewalt, MD, Frederick R. Appelbaum, MD, Harry P. Erba, MD PhD, Elihu H. Estey, MD

Blood (2017) 130 (Supplement 1): 1301.

https://doi.org/10.1182/blood.V130.Suppl_1.1301.1301

Published: 2017

Journal Articles

Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen

Sebastian Ochsenreither, Ravindra Majeti, Thomas Schmitt, Derek Stirewalt, Ulrich Keilholz, Keith R. Loeb, Brent Wood, Yongiae E. Choi, Marie Bleakley, Edus H. Warren, Michael Hudecek, Yoshiki Akatsuka, Irving L. Weissman, Philip D. Greenberg

Blood (2012) 119 (23): 5492–5501.

https://doi.org/10.1182/blood-2011-07-365890

Published: 2012

Includes: Supplemental data

Journal Articles

Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML – A Report From the Children's Oncology Group.

Jason N. Berman, MD, Robert B. Gerbing, PhD, Lillian Sung, MD, Kristen Miller, BS, Jessica A. Pollard, MD, Phoenix Ho, Derek Stirewalt, Jerald Radich, MD, Craig A. Hurwitz, MD, Nyla A. Heerema, PhD, Betsy Hirsch, MD, Susana C. Raimondi, PhD, Beverly Lange, MD, Alan S. Gamis, MD, Janet L. Franklin, MD, MPH, Todd A. Alonzo, PhD, Soheil Meshinchi, MD, PhD

Blood (2009) 114 (22): 3115.

https://doi.org/10.1182/blood.V114.22.3115.3115

Published: 2009

Journal Articles

Prevalence and Prognostic Implications of WT1 Mutations in Pediatric AML Â: Report from Children’s Oncology Group

Jessica A Pollard, Rong Zeng, Phoenix Ho, Todd Alonzo, PhD, Robert Gerbing, Derek Stirewalt, Nyla A. Heerema, PhD, Susana C. Raimondi, PhD, Betsy Hirsch, Janet Franklin, MD, MPH, Beverly Lange, MD, Soheil Meshinchi, MD, PhD

Blood (2008) 112 (11): 143.

https://doi.org/10.1182/blood.V112.11.143.143

Published: 2008

Journal Articles

Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia

Pamela S. Becker, MD, PhD, Elihu Estey, MD, Stephen Petersdorf, MD, Paul C. Hendrie, MD, PhD, John M. Pagel, MD, PhD, Derek Stirewalt, MD, Andrei Shustov, MD, Barry E. Storer, PhD, Frederick R. Appelbaum, MD

Blood (2008) 112 (11): 2964.

https://doi.org/10.1182/blood.V112.11.2964.2964

Published: 2008

Journal Articles

Preferentially Expressed Antigen in Melanoma (PRAME) Expression in Normal and CML CD34+ Progenitor Cells Impairs Myeloid Differentiation.

Vivian Oehler, Carrie Cummings, Kathleen Sabo, Brent Wood, Katherine Guthrie, Ted Gooley, Era Pogosova-Agadjanyan, Paula Ladne, Derek Stirewalt, Janis L. Abkowitz, Jerald Radich

Blood (2008) 112 (11): 1071.

https://doi.org/10.1182/blood.V112.11.1071.1071

Published: 2008

Journal Articles

CEBPA Mutations Predict Favorable Prognosis in Pediatric AML

Phoenix Ho, Todd A. Alonzo, Robert B. Gerbing, Jessica A. Pollard, Derek Stirewalt, Craig Alan Hurwitz, Nyla A. Heerema, Betsy Hirsch, Susana C. Raimondi, Beverly Lange, Janet Franklin, Jerald Radich, Soheil Meshinchi

Blood (2008) 112 (11): 142.

https://doi.org/10.1182/blood.V112.11.142.142

Published: 2008

Journal Articles

FOXC1, a New Prognostic Marker in Adult Acute Myeloid Leukemia (AML).

Odile Blanchet, MD, PhD, Frederique Galopin, MD, Derek Stirewalt, MD, Mathilde Hunault-Berger, MD, PhD, Annaelle Beucher, Era Pogosova-Agadjanyan, Lejla Ibricevic, MD, Laurence Baranger, MD, Franck Genevieve, MD, Marc Zandecki, MD, PhD, Norbert Ifrah, MD, Jerald P. Radich, MD, Philippe Guardiola, MD

Blood (2007) 110 (11): 2387.

https://doi.org/10.1182/blood.V110.11.2387.2387

Published: 2007

NARROW

Identification of a Novel AML Patient Subset Sensitive to Venetoclax Using Matched Proteomics and Diverse Ex Vivo Models

Characteristics and Prognostic Effects of DNMT3A Co-Mutations

A Robust Long Non-Coding RNA Expression Classifier for Risk Stratification in Pediatric AML

Requirement for N 6 -Methyladenosine mRNA Methylation during Human Erythropoiesis

Therapeutic Targeting of Spliceosome Mutant Myeloid Neoplasms Via PARP1 Inhibition

MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia By Enhancing Common β Chain Cytokine Receptor Endocytosis

Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report

Global Proteomic Profiling Identifies Novel Prognostic Factors in Undifferentiated Leukemia Blasts from Patients with NPM1 Mutations: A Previously Unreported Approach to Biomarker Discovery from the Fred Hutch and SWOG

A Shared SF3B1 Neoantigen Is Presented on Primary Malignant Cells and Induced Pluripotent Stem Cell-Derived Hematopoietic Lines

Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG

Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

2 nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials

Associations between Complete Remissions (CRs) with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia and 2-3 Year Survival ("Potential Cure") over the Past Four Decades: Analysis of SWOG Trial Data

Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen

Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML – A Report From the Children's Oncology Group.

Prevalence and Prognostic Implications of WT1 Mutations in Pediatric AML Â: Report from Children’s Oncology Group

Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia

Preferentially Expressed Antigen in Melanoma (PRAME) Expression in Normal and CML CD34+ Progenitor Cells Impairs Myeloid Differentiation.

CEBPA Mutations Predict Favorable Prognosis in Pediatric AML

FOXC1, a New Prognostic Marker in Adult Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only